KR102090408B1 - Premixed composition for beverage containing increased ginsenoside Re, Rd2, F2 and protopanaxdiol and preparation method thereof - Google Patents
Premixed composition for beverage containing increased ginsenoside Re, Rd2, F2 and protopanaxdiol and preparation method thereof Download PDFInfo
- Publication number
- KR102090408B1 KR102090408B1 KR1020180146396A KR20180146396A KR102090408B1 KR 102090408 B1 KR102090408 B1 KR 102090408B1 KR 1020180146396 A KR1020180146396 A KR 1020180146396A KR 20180146396 A KR20180146396 A KR 20180146396A KR 102090408 B1 KR102090408 B1 KR 102090408B1
- Authority
- KR
- South Korea
- Prior art keywords
- powder
- ginseng
- sprout
- ginsenoside
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 235000013361 beverage Nutrition 0.000 title claims abstract description 50
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 title claims abstract description 33
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 title claims abstract description 20
- ZTQSADJAYQOCDD-FDDSVCGKSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O ZTQSADJAYQOCDD-FDDSVCGKSA-N 0.000 title claims abstract description 19
- SWIROVJVGRGSPO-JBVRGBGGSA-N ginsenoside F2 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SWIROVJVGRGSPO-JBVRGBGGSA-N 0.000 title claims abstract description 19
- SWIROVJVGRGSPO-UHFFFAOYSA-N Ginsenoside F2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O SWIROVJVGRGSPO-UHFFFAOYSA-N 0.000 title claims abstract description 17
- AVTXSAWPGCSYFO-UHFFFAOYSA-N Ginsenoside Ia Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O AVTXSAWPGCSYFO-UHFFFAOYSA-N 0.000 title claims abstract description 17
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 title claims abstract description 17
- PYXFVCFISTUSOO-VUFVRDRTSA-N (20R)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-VUFVRDRTSA-N 0.000 title description 17
- 238000002360 preparation method Methods 0.000 title description 12
- 235000008434 ginseng Nutrition 0.000 claims abstract description 84
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 83
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 83
- 239000000843 powder Substances 0.000 claims abstract description 75
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 claims abstract description 17
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 claims abstract description 17
- 241000208340 Araliaceae Species 0.000 claims abstract 10
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 claims abstract 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 30
- 241000283707 Capra Species 0.000 claims description 18
- 238000000855 fermentation Methods 0.000 claims description 16
- 230000004151 fermentation Effects 0.000 claims description 15
- 229960003080 taurine Drugs 0.000 claims description 15
- 235000000346 sugar Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 240000001929 Lactobacillus brevis Species 0.000 claims description 8
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000010025 steaming Methods 0.000 claims description 7
- 150000008163 sugars Chemical class 0.000 claims description 5
- 239000002131 composite material Substances 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims 2
- 229940072205 lactobacillus plantarum Drugs 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 18
- 229930003935 flavonoid Natural products 0.000 abstract description 9
- 150000002215 flavonoids Chemical class 0.000 abstract description 9
- 235000017173 flavonoids Nutrition 0.000 abstract description 9
- 230000003078 antioxidant effect Effects 0.000 abstract description 8
- 235000013824 polyphenols Nutrition 0.000 abstract description 8
- 235000016213 coffee Nutrition 0.000 abstract description 7
- 235000013353 coffee beverage Nutrition 0.000 abstract description 7
- 235000013336 milk Nutrition 0.000 abstract description 7
- 239000008267 milk Substances 0.000 abstract description 7
- 210000004080 milk Anatomy 0.000 abstract description 7
- 235000013322 soy milk Nutrition 0.000 abstract description 7
- 235000013618 yogurt Nutrition 0.000 abstract description 7
- 235000015203 fruit juice Nutrition 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 description 75
- 230000000052 comparative effect Effects 0.000 description 31
- 230000002292 Radical scavenging effect Effects 0.000 description 17
- 229930182494 ginsenoside Natural products 0.000 description 15
- 238000002835 absorbance Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 229940089161 ginsenoside Drugs 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000186660 Lactobacillus Species 0.000 description 7
- 235000002789 Panax ginseng Nutrition 0.000 description 7
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 229940039696 lactobacillus Drugs 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 235000017709 saponins Nutrition 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- 229920002774 Maltodextrin Polymers 0.000 description 5
- 239000005913 Maltodextrin Substances 0.000 description 5
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 5
- 235000012907 honey Nutrition 0.000 description 5
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 5
- 229940035034 maltodextrin Drugs 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 235000009120 camo Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000005607 chanvre indien Nutrition 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011487 hemp Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019629 palatability Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- -1 protopanaxadiol diol Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- KMVWNDHKTPHDMT-UHFFFAOYSA-N 2,4,6-tripyridin-2-yl-1,3,5-triazine Chemical compound N1=CC=CC=C1C1=NC(C=2N=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 KMVWNDHKTPHDMT-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283708 Capra aegagrus Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVLHOJXLNBFHDX-XHJPDDKBSA-N Panaxadiol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(CC[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 PVLHOJXLNBFHDX-XHJPDDKBSA-N 0.000 description 1
- SYFJYASKXNAXKC-UHFFFAOYSA-N Panaxadiol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CCC34C SYFJYASKXNAXKC-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 238000002792 antioxidant assay Methods 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000006153 eosin methylene blue Substances 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 1
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/121—Brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A23Y2220/13—
-
- A23Y2220/67—
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 진세노사이드 Re, Rd2, F2 및 프로토파낙사디올이 강화된 음료용 프리믹스 조성물 및 그 제조방법에 관한 것으로, 더 상세하게는 활성산양삼 분말과 새싹삼 분말을 포함하여 진세노사이드 Re, Rd2, F2 및 프로토파낙사디올의 함량이 현저히 강화된 음료용 프리믹스 조성물 및 그 제조방법에 관한 것이다.The present invention relates to a ginsenoside Re, Rd2, F2 and protopanaxadiol-enhanced premix composition for beverages and a method for manufacturing the same, more specifically, ginsenoside Re, including active goat ginseng powder and sprout ginseng powder. Rd2, F2 and the content of the protopanaxadiol relates to a premix composition for beverages with a significantly enhanced content and a method for manufacturing the same.
삼은 약 60%의 탄수화물, 8~15%의 조단백질, 1~3%의 조지방, 4~6%의 회분, 3~7%의 조사포닌, 그 외 미량성분들로 구성되어 있다. 삼의 기능성으로는 면역력 개선, 피로회복, 기억력 개선, 혈행 개선, 항산화 효과 및 갱년기 여성 건강 등이 있으며, 그 외 중추신경 억제 및 흥분 작용, 단백질 및 핵산 생합성 촉진 작용, 조혈 작용, 동맥경화 예방, 혈당강하 작용, 항피로 및 항스트레스 작용 등의 약리작용도 보고되어 있으며, 이와 같은 작용은 사포닌으로부터 당이 분리되면서 생성된 진세노사이드의 작용에 기인하는 것으로 알려져 있다 (등록특허 10-1152089호).Hemp consists of about 60% carbohydrates, 8-15% crude protein, 1-3% crude fat, 4-6% ash, 3-7% irradiated saponin, and other trace components. The functions of hemp include immunity improvement, fatigue recovery, memory improvement, blood circulation improvement, antioxidant effect, and menopausal women's health, and other central nervous system suppression and excitability, protein and nucleic acid biosynthesis promotion, hematopoiesis, and atherosclerosis prevention, Pharmacological effects such as hypoglycemic action, anti-fatigue and anti-stress action have also been reported, and such action is known to be attributable to the action of ginsenoside produced by the separation of sugar from saponin (Patent No. 10-1152089) .
현재까지 30여 종이 넘는 진세노사이드가 삼 사포닌으로부터 분리동정되었으며, 프로토파낙사디올계 사포닌에 속하는 진세노사이드 Rb1, Rb2, Rc, Rd와 프로토파낙사트리올계 사포닌에 속하는 진세노사이드 Re와 Rg1이 대부분을 차지하고 있다.To date, more than 30 ginsenosides have been identified and separated from hemp saponins, ginsenosides Rb1, Rb2, Rc, Rd belonging to the protopanaxadiol-based saponins, and ginsenosides Re and Rg1 belonging to the protopanaxatriol-based saponins. This accounts for most.
산양삼은 오가피과에 속하며 다년생 초목인 인삼(Panax ginseng)이 산간의 삼림하의 야생상태에서 자연적으로 성장한 산삼의 씨앗이나 유삼을 인위적으로 산에서 재배한 것을 말한다. 산양삼은 여러 효능면에서 재배 인삼보다 효과가 더 높은 것으로 알려져 있으나 이를 뒷받침할 수 있는 과학적 근거가 인삼에 비해 그리 많지는 않은 것이 현재 실정이다. 또한 알려진 산양삼 관련 가공품들은 진세노사이드 함유량이 기준치 미달인 실정이다. 이에 진세노사이드 함량이 증진된 산양삼 가공품의 개발이 요구되고 있는 실정이다.Goat ginseng belongs to the family Ogapiaceae and refers to artificially cultivated seeds or ginseng of wild ginseng grown naturally in wild conditions under the mountain forest by the perennial vegetation, Panax ginseng . It is known that goats are more effective than cultivated ginseng in many efficacy, but there is not much scientific evidence to support them compared to ginseng. Also, known ginseng-related processed products have a ginsenoside content below the standard. Accordingly, there is a need for the development of processed ginseng ginseng with an enhanced ginsenoside content.
이에 본 발명자들은 종래 기술의 요구에 부응하기 위해 연구를 지속한 결과, 산양삼을 복합발효하여 제조한 활성산양삼과 새싹삼을 조합하여 포함하는 음료용 프리믹스 조성물은 진세노사이드 Re, Rd2, F2 및 프로토파낙사디올의 함량이 현저히 강화되고, 휴대가 용이하고, 물, 커피, 우유, 두유, 또는 요구르트에 첨가하여 음료로 섭취가 용이하다는 것을 확인하고 본 발명을 완성하게 되었다. As a result, the present inventors continued research to meet the needs of the prior art. As a result, the premix composition for beverages comprising a combination of active wild ginseng and sprout ginseng prepared by complex fermentation of wild ginseng is ginsenoside Re, Rd2, F2 and prototype The content of panaxadiol is significantly enhanced, easy to carry, and added to water, coffee, milk, soy milk, or yogurt to confirm that it is easy to consume as a beverage and to complete the present invention.
따라서 본 발명의 목적은 활성산양삼 분말 및 새싹삼 분말을 포함하여 진세노사이드 Re, Rd2, F2 및 프로토파낙사디올의 함량이 현저히 강화된 음료용 프리믹스 조성물을 제공하는 것이다. Accordingly, an object of the present invention is to provide a premix composition for beverages in which the content of ginsenoside Re, Rd2, F2, and protopanaxadiol is remarkably enhanced, including active goat ginseng powder and sprout ginseng powder.
본 발명의 또 다른 목적은 진세노사이드 Re, Rd2, F2 및 프로토파낙사디올의 함량이 현저히 강화된 음료용 프리믹스 조성물의 제조방법을 제공하는 것이다.Another object of the present invention is to provide a method for preparing a premix composition for beverages in which the content of ginsenoside Re, Rd2, F2 and protopanaxadiol is significantly enhanced.
상기 목적을 달성하기 위해, 본 발명은 활성산양삼 분말 1~3 중량%, 새싹삼 분말 2~8 중량%, 타우린 1~3 중량% 및 나머지 분말상 당류를 포함하는 음료용 프리믹스 조성물을 제공한다. In order to achieve the above object, the present invention provides a premix composition for beverages comprising 1 to 3% by weight of active goat ginseng powder, 2 to 8% by weight of sprout ginseng powder, 1 to 3% by weight of taurine, and the remaining powdered sugars.
활성산양삼 분말Active ginseng powder
본 발명의 음료용 프리믹스 조성물은 활성산양삼 분말을 유효성분으로 포함한다. The premix composition for beverages of the present invention includes active goat ginseng powder as an active ingredient.
본 발명에서 '활성산양삼'은 증숙 후 복합발효하여 제조되는 것으로 진세노사이드 Re, Rd2, F2 및 프로토파낙사디올 함량이 증진되도록 산양삼을 가공한 것을 말한다. In the present invention, 'active mountain ginseng' is produced by complex fermentation after steaming, and refers to processing of wild ginseng so that the content of ginsenoside Re, Rd2, F2 and protopanaxadiol is enhanced.
본 발명에서 '증숙'은 100℃에서 30~60분간 수증기로 찌는 것을 의미한다. 증숙시간이 30분 미만인 경우 충분한 증숙이 진행되지 않아 잡균의 오염이 발생될 수 있으며, 60분 초과하여 증숙될 경우는 오랜 열처리로 산양삼의 생리활성성분이 파괴될 수 있다.In the present invention, 'steaming' means steaming with water vapor at 100 ° C for 30 to 60 minutes. When the steaming time is less than 30 minutes, sufficient steaming does not proceed, resulting in contamination of germs, and when steaming for more than 60 minutes, the bioactive components of wild ginseng can be destroyed by a long heat treatment.
본 발명에서 '복합발효'는 증숙된 산양삼을 락토바실러스 플란타륨 P1201 균주와 락토바실러스 브레비스 WCP02 균주의 복합 종균으로 발효한다.In the present invention, 'composite fermentation' ferments fermented wild ginseng as a complex seed of the Lactobacillus plantarium P1201 strain and the Lactobacillus brevis WCP02 strain.
본 발명에서 복합종균을 구성하는 하나의 균주인 락토바실러스 플란타륨 P1201 균주는 본 발명자들이 발효식품으로부터 분리/동정하여 국립농업과학원 농업유전자원센터(KACC)에 2013년 7월 19일에 기탁한 균주(수탁번호 KACC91848P)로서, 생균제제능이 우수하고 생리활성물질 생산성이 우수한 특성을 갖는다 (등록특허 10-154418호).Lactobacillus plantarium P1201 strain, which is one strain constituting the complex seed in the present invention, was isolated / identified from the fermented foods by the present inventors and deposited with the National Institute of Agricultural Science, Agricultural Genetic Resource Center (KACC) on July 19, 2013. As a strain (Accession No. KACC91848P), it has excellent probiotic performance and excellent bioactive material productivity (Registration No. 10-154418).
본 발명에서 복합종균을 구성하는 또 다른 하나의 균주인 락토바실러스 브레비스 WCP02 균주는 본 발명자들이 김치로부터 분리/동정하여 국립농업과학원 농업유전자원센터(KACC)에 2016년 12월 12일에 기탁한 균주(수탁번호 KACC92159P)로, 위액산 내성과 담즙산 내성이 우수하고 가바(GABA)의 생산성이 탁월하다 (특허출원 10-2017-0102863호).Another strain constituting the complex spawn in the present invention, the Lactobacillus brevis WCP02 strain is a strain deposited by the present inventors on December 12, 2016 at the National Center for Agricultural Genetic Resources (KACC), separated / identified from kimchi. With accession number KACC92159P, gastric acid resistance and bile acid resistance are excellent, and the productivity of GABA is excellent (Patent Application No. 10-2017-0102863).
본 발명의 복합종균을 구성하는 락토바실러스 플란타륨 P1201 균주와 락토바실러스 브레비스 WCP02 균주는 발효 특성이 상호 보완되어 상승작용을 나타낸다. 락토바실러스 플란타륨 P1201 균주는 동형유산발효(homo-lactic acid fermentation) 유산균으로 단독 발효 시 유산이 과다하게 생성되고, 락토바실러스 브레비스 WCP02 균주는 이형유산발효 (hetero-lactic acid fermentation) 유산균으로 단독 발효 시 유산 생성이 충분하지 않는데, 놀랍게도 산양삼을 이들 두 가지 종균을 함께 사용하여 복합발효시 양 균주의 발효 특성이 상호 보완되고 진세노사이드 Re, Rd2, F2 및 프로토파낙사디올의 함량이 현저히 증진되었다.The Lactobacillus plantarium P1201 strain and the Lactobacillus brevis WCP02 strain constituting the complex seed of the present invention exhibit synergistic effects by complementing the fermentation properties. Lactobacillus plantarium P1201 strain is a homo-lactic acid fermentation lactic acid bacterium, and when fermented alone, excessive lactic acid is generated. The production of lactic acid is not sufficient. Surprisingly, the fermentation characteristics of both strains were complemented and the content of ginsenoside Re, Rd2, F2, and protopanaxadiol was significantly enhanced when using wild goat ginseng together with these two species. .
본 발명에서 복합 종균은 락토바실러스 플란타륨 P1201 균주와 락토바실러스 브레비스 WCP02 균주는 각각 별도의 배양액으로서 첨가될 수도 있으며, 혼합 배양된 혼합 배양액으로서 첨가될 수도 있다. 복합종균에서 상기 2종의 균주의 혼합 비율은 3 : 1 ~ 1 : 3(v/v)으로 혼합될 수 있다.In the present invention, the complex seed strains may be added as a Lactobacillus plantarium P1201 strain and a Lactobacillus brevis WCP02 strain as separate culture media, or as a mixed culture culture mixture. The mixing ratio of the two strains in the complex seed can be mixed in a ratio of 3: 1 to 1: 3 (v / v).
본 발명에서 발효는 복합 종균의 배양액을 증숙된 산양삼에 5∼15% 접종하여 30∼35℃에서 3~7일 발효하는 것으로 수행될 수 있다. 복합 종균 접종량이 5%(v/w) 미만일 경우에는 발효 속도가 지연될 수 있고 15%(v/w) 초과 시에는 균체 증식 속도가 빨라 활성 진세노사이드의 전환율이 낮으며 신맛이 등이 과다할 수 있으며, 발효 온도가 30℃ 미만일 경우 유산균의 생육이 저하되어 발효기간이 길어지고 잡균의 오염을 초래하고 35℃를 초과할 경우에는 균주의 생육 저하로 인해 원활한 발효가 이루어지지 않고, 발효 기간이 3일 미만일 경우 발효가 충분하지 않아 생리활성물질 등의 생성이 저조하게 될 수 있으며, 7일을 초과한 경우는 과발효에 의해 생리활성물질이 분해될 수 있다.In the present invention, fermentation may be performed by inoculating 5-15% of the culture of the complex seed germ in boiled wild ginseng at 3 to 7 days at 30 to 35 ° C. The fermentation rate may be delayed when the combined seed inoculation amount is less than 5% (v / w), and when it exceeds 15% (v / w), the cell growth rate is fast, so the conversion rate of active ginsenoside is low and the sour taste is excessive. When the fermentation temperature is less than 30 ℃, the growth of lactic acid bacteria decreases, resulting in a long fermentation period and contamination of various germs, and when it exceeds 35 ℃, the fermentation period does not occur smoothly due to a decrease in the growth of the strain. If it is less than 3 days, the fermentation is insufficient, and thus the production of physiologically active substances may be poor, and if it exceeds 7 days, the bioactive substances may be decomposed by over-fermentation.
분말화는 복합발효되어 제조된 활성산양삼을 40∼55℃에서 3~5일 건조하고 100 메쉬 이상으로 분쇄하는 과정으로 수행될 수 있다. Powdering may be performed by drying the active ginseng prepared by complex fermentation at 40 to 55 ° C. for 3 to 5 days and crushing it to 100 mesh or more.
본 발명의 복합발효된 활성산양삼 분말은 음료용 프리믹스 조성물에 첨가시 진세노사이드 Re, Rd2, F2 및 프로토파낙사디올을 강화되게 한다. The complex fermented active ginseng powder of the present invention strengthens ginsenoside Re, Rd2, F2 and protopanaxadiol when added to a premix composition for beverages.
본 발명의 음료용 프리믹스 조성물에서 활성산양삼 분말은 1~3 중량%로 포함하는데, 1 중량% 미만이면 진세노사이드 Re, Rd2, F2 및 프로토파낙사디올의 강화를 기대하기 어렵고 3 중량% 초과이면 제조시 비용 상승 문제가 발생하고, 진세노사이드 함량이 높아 인체에 독성을 유발할 수 있다.In the premix composition for beverages of the present invention, the active red ginseng powder is contained in 1 to 3% by weight, and if it is less than 1% by weight, it is difficult to expect to strengthen the ginsenoside Re, Rd2, F2 and protopanaxadiol, and if it exceeds 3% by weight During manufacturing, there is a problem of cost increase and high ginsenoside content, which may cause toxicity to the human body.
새싹삼Sprout 분말 powder
본 발명의 음료용 프리믹스 조성물은 새싹삼 분말을 유효성분으로 포함한다.The premix composition for beverages of the present invention contains the sprout sprout powder as an active ingredient.
새싹삼은 묘삼(파종 후 일 년 남짓 자란 어린 인삼) 중 24개월 미만의 삼을 특수배양토 및 시설에서 재배하는 것으로 화학농약을 사용하지 않은 청정한 환경관리 기술로 단기간(30~40일)에 재배한 수삼이다. 새싹삼은 사포닌 함량이 기존 수삼보다 월등히 높으며, 뿌리보다 잎에 사포닌 함량이 6~8배 높게 함유되어 있다. 새싹삼은 뿌리뿐만 아니라 줄기와 잎까지 전초를 섭취할 수 있다. Ginseng sprouts (young ginseng grown more than a year after sowing) are grown in special culture soils and facilities for less than 24 months, and ginseng grown in a short period of time (30-40 days) with clean environmental management technology without chemical pesticides to be. The sprout saponin content is significantly higher than that of the existing ginseng, and the saponin content is 6 ~ 8 times higher in the leaves than the root. You can take outpost from the sprouted roots to the stems and leaves.
본 발명에서 새싹삼 분말은 새싹삼 전초를 40∼55℃에서 3~5일 건조하고 100 메쉬 이상으로 분쇄하여 제조한다.In the present invention, the sprout sprout powder is prepared by drying the sprout sprout outpost at 40 to 55 ° C. for 3 to 5 days and pulverizing to 100 mesh or more.
본 발명의 음료용 프리믹스 조성물에서 새싹삼 분말은 2~8 중량%로 포함하는데, 2 중량% 미만이면 생리활성이 미흡해지고, 8 중량% 초과이면 단가 상승의 문제점이 발생될 수 있다.In the premix composition for beverages of the present invention, the sprout ginseng powder contains 2 to 8% by weight, but if it is less than 2% by weight, physiological activity is insufficient, and if it exceeds 8% by weight, a problem of a rise in unit price may occur.
타우린Taurine
본 발명의 음료용 프리믹스 조성물은 타우린을 1~3 중량%로 포함한다. The premix composition for beverages of the present invention contains 1 to 3% by weight of taurine.
타우린은 아미노산의 일종으로, 식물에는 거의 함유되어 있지 않으나 인간의 주요 장기에는 다량 함유되어 있으나, 인체에서 타우린의 생합성은 극히 제한적이다. 타우린은 뇌의 교감신경에 대해 억제작용을 나타내고, 운동 능력을 향상시키고 불안 증세를 완화시킬 수 있으며, 저밀도 지단백질(LDL) 콜레스테롤 생성 억제를 통해 각종 혈관계 질환 예방에도 효과가 있다. Taurine is a type of amino acid, which is rarely contained in plants, but is abundant in major human organs, but the biosynthesis of taurine in the human body is extremely limited. Taurine exhibits an inhibitory effect on the sympathetic nerves of the brain, can improve motor skills and alleviate anxiety symptoms, and is also effective in preventing various vascular diseases by suppressing low-density lipoprotein (LDL) cholesterol production.
타우린은 상업적으로 용이하게 입수할 수 있다. Taurine is readily available commercially.
본 발명의 음료용 프리믹스 조성물에서 타우린이 1 중량% 미만이면 타우린의 기능성인 간과 심장의 기능 강화 또는 콜레스테롤 감소효과를 기대하기 어렵고, 3 중량% 초과이면 과다 섭취로 인해 위궤양 혹은 설사와 같은 부작용이 나타날 수 있다. In the premix composition for beverages of the present invention, if the taurine is less than 1% by weight, it is difficult to expect the function of taurine to enhance the function of liver and heart or reduce cholesterol, and if it exceeds 3% by weight, side effects such as gastric ulcer or diarrhea may occur due to excessive consumption. You can.
분말상Powder 당류 sugars
본 발명의 음료용 프리믹스 조성물은 분말상 당류를 포함한다. The premix composition for beverages of the present invention contains a powdered sugar.
분말상 당류로는 꿀 분말, 말토덱스트린 분말, 미립당 분말, 과일 분말, 설탕 분말, 스테비아, 아스파탐 등을 하나 이상 조합하여 사용할 수 있다. As the powdered sugar, honey powder, maltodextrin powder, fine sugar powder, fruit powder, sugar powder, stevia, aspartame, or the like can be used in combination.
가장 바람직하게는 분말상 당류는 꿀 분말, 말토덱스트린 분말 및 미립당 분말을 중량비로 3∼10%, 8∼12% 및 75∼85%로 조합하여 사용한다. Most preferably, the powdered saccharides are honey powder, maltodextrin powder and fine sugar powder in a weight ratio of 3 to 10%, 8 to 12% and 75 to 85% in combination.
필요에 따라서, 본 발명의 음료용 프리믹스 조성물은 비타민, 비타민복합체, 아미노산제 등의 첨가제를 추가로 포함할 수 있다. If necessary, the beverage premix composition of the present invention may further include additives such as vitamins, vitamin complexes, and amino acid agents.
본 발명에 따른 음료용 프리믹스 조성물은 진세노사이드 Re, Rd2, F2 및 프로토파낙사디올의 함량이 각각 0.21 mg/g 이상, 0.09 mg/g 이상, 0.20 mg/g 이상, 0.19 mg/g 이상으로 강화되어, 비교예에 비하여 각각 0.21배, 4.5배, 5배, 3.8배 이상 증진된다 (표 3).In the premix composition for beverages according to the present invention, the content of ginsenoside Re, Rd2, F2 and protopanaxadiol is 0.21 mg / g or more, 0.09 mg / g or more, 0.20 mg / g or more, and 0.19 mg / g or more, respectively. It is enhanced, and is 0.21 times, 4.5 times, 5 times, 3.8 times or more enhanced compared to the comparative example (Table 3).
또한 본 발명에 따른 음료용 프리믹스 조성물은 페놀릭스와 플라보노이드 함량이 현저히 증진되어서 우수한 항산화 활성을 가진다 (도 3, 도 4). In addition, the premix composition for beverages according to the present invention has excellent antioxidant activity due to remarkably enhanced phenolics and flavonoid contents (FIGS. 3 and 4).
본 발명에 따른 음료용 프리믹스 조성물은 미세분말로 되어 있어 물, 커피, 우유, 두유, 요구르트, 과일 주스 등에 잘 녹아 섭취가 용이하다. The premix composition for beverages according to the present invention is made of fine powder, so it is easily dissolved in water, coffee, milk, soy milk, yogurt, fruit juice, and the like.
본 발명의 또 다른 목적에 따라서, 본 발명은 상기 조성물을 포함하는 음료를 제공한다. According to another object of the present invention, the present invention provides a beverage comprising the composition.
본 발명에서 음료는 커피, 우유, 두유, 요구르트 과일 주스 등이다.Beverages in the present invention are coffee, milk, soy milk, yogurt fruit juice, and the like.
또한 본 발명의 음료용 프리믹스 조성물은 커피, 우유, 두유, 요구르트 과일 주스 등과 맛과 향이 서로 잘 조화되어 기호성 또한 우수하다.In addition, the premix composition for beverages of the present invention is excellent in palatability because the taste and aroma of coffee, milk, soy milk, yogurt fruit juice and the like are well harmonized with each other.
본 발명의 또 다른 목적에 따라서, 본 발명은 According to another object of the present invention, the present invention
ⅰ) 산양삼을 100℃에서 30~60분간 증숙한 후 락토바실러스 플란타륨 P1201 균주와 락토바실러스 브레비스 WCP02 균주의 복합 종균으로 발효하여 40∼55℃에서 3~5일 건조하고 100 메쉬 이상으로 분쇄하여 활성산양삼 분말을 제조하는 단계;Iv) After fermenting wild ginseng at 100 ℃ for 30 ~ 60 minutes, fermentation into a complex strain of Lactobacillus plantarium P1201 strain and Lactobacillus brevis WCP02 strain, dried for 3 ~ 5 days at 40 ~ 55 ℃ and crushed to 100 mesh or more Preparing an active goat ginseng powder;
ⅱ) 새싹삼 전초를 40∼55℃에서 3~5일 건조하고 100 메쉬 이상으로 분쇄하여 새싹삼 분말을 제조하는 단계; 및Ii) preparing sprout sprout powder by drying the sprout sprout outpost at 40-55 ° C. for 3 to 5 days and crushing to 100 mesh or more; And
ⅲ) 활성산양삼 분말 1~3 중량%, 새싹삼 분말 2~8 중량%, 타우린 1~3 중량% 및 나머지 분말상 당류를 혼합하는 단계를 포함하여 이루어지는 진세노사이드 Re, Rd2, F2 및 프로토파낙사디올의 함량이 현저히 강화된 음료용 프리믹스 조성물의 제조방법을 제공한다. Iv) Ginsenoside Re, Rd2, F2 and Protopanaxa, which comprises mixing 1 ~ 3% by weight of active red ginseng powder, 2 ~ 8% by weight of sprouted ginseng powder, 1 ~ 3% by weight of taurine and the remaining powdery sugars Provided is a method for preparing a premix composition for beverages having a significantly enhanced diol content.
필요에 따라서, 본 발명의 음료용 프리믹스 조성물의 제조방법은 단계 ⅲ)에서 비타민, 비타민 복합체, 아미노산제 등의 첨가제를 추가로 포함하여 혼합할 수 있다. If necessary, the method for preparing a premix composition for beverages of the present invention can be mixed by further including additives such as vitamins, vitamin complexes, and amino acid agents in step iv).
필요에 따라서, 본 발명의 음료용 프리믹스 조성물의 제조방법은 단계 ⅲ) 후에 스틱 용기 등에 조성물을 충진 및 포장하는 단계를 추가로 포함할 수 있다.If necessary, the method for preparing a premix composition for a beverage of the present invention may further include a step of filling and packaging the composition in a stick container after step iii).
본 발명에 따른 음료용 프리믹스 조성물은 활성산양삼 분말과 새싹인삼 분말을 유효성분으로 포함하여 진세노사이드 Re, Rd2, F2 및 프로토파낙사디올 함량이 현저히 강화되고 페놀릭스와 플라보노이드 함량이 증진됨에 따라 항산화 활성이 강화되어서 각종 암 예방, 체중조절과 콜레스테롤 저하와 같은 대사증후군 개선, 혈액순환 개선, 노화방지, 성인병 예방 또는 면연력 증진용 건강기능성 음료의 소재로서 유용하다. The premix composition for beverages according to the present invention contains active red ginseng powder and sprout ginseng powder as active ingredients, thus significantly enhancing the ginsenoside Re, Rd2, F2 and protopanaxadiol diol contents and antioxidants as the phenolics and flavonoid contents are enhanced It is useful as a material for health functional drinks for preventing various cancers, improving metabolic syndrome such as weight control and lowering cholesterol, improving blood circulation, preventing aging, preventing adult diseases, or promoting cotton deprivation due to enhanced activity.
또한 본 발명에 따른 음료용 프리믹스 조성물은 분말형이어서 스틱형 용기에 충진가능하고 휴대가 간편하며, 분말 상태 그대로 섭취할 수도 있고, 물, 커피, 우유, 두유, 요구르트, 과일 주스 등에 첨가하여 섭취할 수 있다. In addition, the premix composition for beverages according to the present invention is powdered, so it can be filled in a stick-type container and easy to carry, and can be consumed as it is, or added to water, coffee, milk, soy milk, yogurt, fruit juice, etc. You can.
또한 본 발명의 음료용 프리믹스 조성물은 물, 커피, 우유, 두유, 요구르트, 과일 주스 등과 맛, 향이 서로 잘 조화되어 기호성 또한 우수하다.In addition, the premix composition for beverages of the present invention is excellent in palatability, because water, coffee, milk, soy milk, yogurt, fruit juice, and the like have good taste and aroma.
도 1은 본 발명에 따른 음료용 프리믹스 조성물의 제조공정의 일례를 나타낸다.
도 2a는 비교예 1의 진세노사이드 HPLC 크로마토그램을 나타낸 것이다. 도 2b는 비교예 2의 진세노사이드 HPLC 크로마토그램이며, 도 2c는 본 발명에 따른 음료용 프리믹스 조성물의 진세노사이드 HPLC 크로마토그램이다.
도 3a는 본 발명에 따른 음료용 프리믹스 조성물의 페놀릭스 함량을 나타낸 것이다.
도 3b는 본 발명에 따른 음료용 프리믹스 조성물의 플라보노이드스 함량을 나타낸 것이다.
도 4는 본 발명에 따른 음료용 프리믹스 조성물의 항산화 활성을 나타낸 것이다. 도 4a는 DPPH 라디칼 소거활성을 나타내고, 도 4b는 ABTS 라디칼 소거활성을 나타내고, 도 4c는 히드록실 라디칼 소거활성을 나타내고, 도 4d는 FRAP 환원력을 나타낸다.1 shows an example of a manufacturing process of a premix composition for beverages according to the present invention.
Figure 2a shows the ginsenoside HPLC chromatogram of Comparative Example 1. Figure 2b is a ginsenoside HPLC chromatogram of Comparative Example 2, Figure 2c is a ginsenoside HPLC chromatogram of the premix composition for beverages according to the present invention.
Figure 3a shows the phenolics content of the premix composition for beverages according to the present invention.
Figure 3b shows the flavonoids content of the premix composition for beverages according to the present invention.
Figure 4 shows the antioxidant activity of the premix composition for beverages according to the present invention. 4A shows DPPH radical scavenging activity, FIG. 4B shows ABTS radical scavenging activity, FIG. 4C shows hydroxyl radical scavenging activity, and FIG. 4D shows FRAP reducing power.
다음의 실시예들에 의해 본 발명이 더 상세히 설명된다. 이들 실시예는 본 발명을 예시하기 위한 것이며, 본 발명의 범위가 이들에 의해 제한되어서는 안된다.The invention is explained in more detail by the following examples. These examples are intended to illustrate the invention, and the scope of the invention should not be limited by them.
제조예 1: 활성산양삼 분말 및 새싹삼 분말 제조Preparation Example 1: Preparation of active goat ginseng powder and sprout ginseng powder
3년 이상 재배근 산양삼 5 kg을 흐르는 물에 3회 이상 세척하여 흙과 먼지를 제거하고 스텐 찜통에 담은 후 100℃에서 60분간 증숙하였다. 증숙된 산양삼을 적당히 식힌 후 여기에 미리 배양해둔 락토바실러스 플란타륨 P1201 및 락토바실러스 브레비스 WCP02 균주 배양액을 5%(v/v) 비율로 접종하고 35℃에서 7일간 정치 발효하였다. 복합발효된 활성산양삼을 사각틀에 가지런히 담은 후 55℃로 설정되어진 드라이 오븐에 넣어 3일간 열풍건조하고 100 메쉬 이상으로 분쇄하여 활성산양삼 분말을 제조하였다.For more than 3 years, cultivated roots were washed 3 times or more in running water of 5 kg of wild ginseng to remove dirt and dust, put in a stainless steel steamer, and then steamed at 100 ℃ for 60 minutes. After adequately cooled boiled wild ginseng, the Lactobacillus plantarium P1201 and Lactobacillus brevis WCP02 strain cultures previously cultured therein were inoculated at a rate of 5% (v / v) and allowed to stand still at 35 ° C for 7 days. After the composite fermented active ginseng was neatly placed in a square frame, it was put in a dry oven set at 55 ° C, hot-air dried for 3 days, and pulverized to 100 mesh or more to prepare active red ginseng powder.
새싹삼 전초 5 kg을 흐르는 물에 3회 이상 깨끗이 세척하여 흙과 이물질을 제거하고 55℃로 설정되어진 드라이오븐에 넣어 3일간 열풍건조하고 100 메쉬 이하로 분쇄시켜 새싹삼 분말을 제조하였다. The sprouts were washed three times or more in flowing water of 5 kg of outpost, removed soil and debris, put into a dry oven set at 55 ° C, dried by hot air for 3 days, and crushed to 100 mesh or less to prepare sprouts powder.
제조예 2: 음료용 프리믹스 조성물 제조Preparation Example 2: Preparation of premix composition for beverages
상기 제조예 1에서 제조된 활성산양삼 분말과 새싹삼 분말과, 타우린 분말, 분말상 당류 (꿀 분말, 말토덱스트린 분말, 미립당) 및 비타민 복합체를 하기 표 1의 배합비율로 혼합하여 음료용 프리믹스 조성물 (실시예)을 제조하였다. 제조된 조성물은 스텐드 스틱충진기로 스틱포장지에 1포당 10 g씩 충진하였다.The premix composition for beverages by mixing the active red ginseng powder, sprouted ginseng powder, taurine powder, powdered saccharides (honey powder, maltodextrin powder, fine sugar) and vitamin complexes prepared in Preparation Example 1 at the mixing ratio shown in Table 1 below. Example) was prepared. The prepared composition was filled with 10 g per bag in a stick wrapping paper with a stand stick filling machine.
비교를 위하여, 활성산양삼 분말과 새싹삼 분말 대신에, 인삼 분말(비교예 1)과 산양삼 분말(비교예 2)를 제조하였다.For comparison, ginseng powder (Comparative Example 1) and goat ginseng powder (Comparative Example 2) were prepared in place of the active goat ginseng powder and sprout ginseng powder.
타우린, 꿀 분말, 미립당, 말토덱스트린 분말, 비타민복합체는 시중에 판매되는 것을 구입하여 사용하였다. 인삼 분말은 산청군 소재 (주)자연애제약에서 공급받아 사용하였고 산양삼 분말은 사천시 소재 (농)드림팜(유한)에서 공급받아 사용하였다. Taurine, honey powder, particulate sugar, maltodextrin powder, and vitamin complexes were purchased and used on the market. Ginseng powder was supplied from Sanae-gun Pharmaceutical Co., Ltd., and Sanyang ginseng powder was supplied from Sacheon-si (Nong) Dream Farm (Yuhan).
(인삼)Comparative Example 1
(Ginseng)
(산양삼)Comparative Example 2
(Goat ginseng)
(활성산양삼+새싹삼)Example
(Active wild ginseng + sprout ginseng)
시험예Test example 1: 음료용 1: For beverage 프리믹스Premix 조성물의 이화학적 특성 Physicochemical properties of the composition
제조예 2에서 제조된 실시예의 음료용 프리믹스 조성물의 이화학적 특성은 pH, 산도, 대장균수 유무로 평가하였다. The physicochemical properties of the premix composition for beverages of Examples prepared in Preparation Example 2 were evaluated by pH, acidity, and the presence or absence of E. coli.
pH는 pH 미터기(모델, 3510, JenWay Essex, UK)를 사용하여 측정하였고 산도는 중화적정법을 적용하여 각각의 조성물의 pH 8.3±0.2까지 중화시키는데 소비된 0.1 N NaOH 용액의 양을 구하고 젖산(%)으로 표시하였다. 대장균수는 식품공전법을 따라 대장균 정성시험을 수행하였고 Eosin Methylene Blue Agar 배지를 사용하여 각 조성물들의 대장균 검출 유무를 알아보고 그람염색을 통해 최종 대장균 유무를 확인하였고, 그 결과를 표 2에 나타냈다.The pH was measured using a pH meter (model, 3510, JenWay Essex, UK), and the acidity was determined by applying the neutralization titration method to obtain the amount of 0.1 N NaOH solution consumed to neutralize to pH 8.3 ± 0.2 of each composition and lactic acid (% ). Escherichia coli water was tested for E. coli according to the Food Code Method, and Eosin Methylene Blue Agar medium was used to find out whether E. coli was detected for each composition, and the presence or absence of the final E. coli was confirmed through Gram staining, and the results are shown in Table 2.
(인삼)Comparative Example 1
(Ginseng)
(산양삼)Comparative Example 2
(Goat ginseng)
(활성산양삼+새싹인삼)Example
(Active wild ginseng + sprout ginseng)
**nd: 검출되지 않음.* All experiments are repeated three times and are expressed as average values.
** nd: not detected.
표 2에 나타낸 바와 같이, 본 발명에 따른 실시예의 음료용 프리믹스 조성물(활성산양삼+새싹인삼 분말 포함)의 pH는 5.85로 측정되었고, 산도는 pH 수치에 비례하여 적당한 산미를 형성하였고, 대장균은 검출되지 않았다.As shown in Table 2, the pH of the premix composition for beverages (including active wild ginseng + sprout ginseng powder) of the embodiment according to the present invention was measured to be 5.85, and the acidity formed a suitable acidity in proportion to the pH value, and E. coli was detected. Did not.
참고예: 추출-농축액 제조Reference Example: Preparation of extract-concentrate
상기 제조예 2에서 제조된 각 조성물 분말 (실시예, 비교예 1 및 2) 10 g씩에 50% 주정을 200 ml을 가한 후 40℃에서 5시간 교반한 후 여과하여 추출물을 제조하였다. 이 추출물을 감압농축기를 이용하여 활성산양삼 분말 중량 대비 동량인 10 ml로 농축하여 추출-농축액을 제조하여, 하기 분석들에 사용하였다.After adding 200 ml of 50% alcohol to 10 g of each composition powder prepared in Preparation Example 2 (Examples, Comparative Examples 1 and 2), the mixture was stirred at 40 ° C. for 5 hours and filtered to prepare an extract. This extract was concentrated to 10 ml, which is equivalent to the weight of the active red ginseng powder, using a reduced pressure concentrator to prepare an extract-concentrate, which was used in the following analyzes.
시험예Test example 2: 진세노사이드 함량 분석 2: Ginsenoside content analysis
제조예 2에서 제조된 실시예의 음료용 프리믹스 조성물과 비교예 1 및 2의 조성물에 대한 진세노사이드 함량 분석을 건강기능성식품 평가 가이드라인에 수록된 방법을 조금 변경하여 고성능 액체 크로마토그래피(HPLC, high performane liquid chromatography)로 분석하였다. High performance liquid chromatography (HPLC, high performane) by slightly changing the method of ginsenoside content analysis of the premix composition for beverages of the Examples prepared in Preparation Example 2 and the compositions of Comparative Examples 1 and 2 in the guideline for evaluation of health functional foods liquid chromatography).
구체적으로는 상기 참조예에서 준비된 각 조성물의 추출-농축액에 HPLC용 물을 2배(v/v)로 첨가하고 혼합한 후 0.45㎛ 멤브레인 필터로 여과한 후 분석시료로 사용하였다.Specifically, the extract-concentrate of each composition prepared in the above reference example was added twice as much as water for HPLC (v / v), mixed, filtered through a 0.45 μm membrane filter, and used as an analysis sample.
분석에 사용된 칼럼은 TSKgel ODS-100Z를 사용하였고 각각의 분석시료 10 ㎕씩 칼럼에 주입하였으며 칼럼의 온도는 좌우 30℃, 유속은 1분당 1.0 mL를 유지하여 203 nm 파장에서 수행하였다. 이때 이동상 용매로는 A와 B를 사용하였고 A 용매는 HPLC water, B 용매는 HPLC 아세토나이트릴로 구성된다. HPLC 분석 조건은 A 용매 기준으로 0분 때 81%, 15분 때 80%, 40분 때 77%, 42분 때 70%, 75분 때 65%, 80분 때 30%, 90분 때 10%로 흐름률을 설정하였다. 분석이 완료된 실시예의 조성물(활성산양삼+새싹인삼), 비교예 1의 조성물(인삼 분말)과 비교예 2의 조성물(산양삼 분말)의 진세노사이드 함량은 표 3 및 도 2에 나타내었다.As a column used for analysis, TSKgel ODS-100Z was used, and 10 µl of each analysis sample was injected into the column, and the column temperature was maintained at 30 ° C on the left and right, and the flow rate was maintained at 1.0 mL per minute at 203 nm. At this time, A and B were used as the mobile phase solvent, the solvent A was composed of HPLC water, and the solvent B was composed of HPLC acetonitrile. HPLC analysis conditions were based on the solvent A: 81% at 0 minutes, 80% at 15 minutes, 77% at 40 minutes, 70% at 42 minutes, 65% at 75 minutes, 30% at 80 minutes, and 10% at 90 minutes. The flow rate was set. The ginsenoside contents of the composition of the Example (active ginseng + sprout ginseng), the composition of Comparative Example 1 (ginseng powder), and the composition of Comparative Example 2 (goat ginseng powder) are shown in Table 3 and FIG. 2.
(인삼)Comparative Example 1
(Ginseng)
(산양삼)Comparative Example 2
(Goat ginseng)
(활성산양삼+새싹인삼)Example
(Active wild ginseng + sprout ginseng)
**nd: 검출되지 않음.* All experiments are repeated three times and are expressed as average values.
** nd: not detected.
도 2에 도시된 바와 같이, 비교예 1(인삼 분말 포함)의 조성물에서는 피크 21번(protopanaxdiol)이 검출되고 나머지는 검출되지 않았다(도 2a). 비교예 2(산양삼 분말 포함)의 조성물에서는 피크 15번(Rd2), 16번(F2), 21번(protopanaxdiol)이 검출되었고 (도 2b), 실시예(활성산양삼+새싹인삼 분말 포함)의 조성물에서는 피크 2번(Re), 15번(Rd2), 16번(F2), 21번(protopanaxdiol) 모두 검출되었다(도 2c).As shown in Fig. 2, in the composition of Comparative Example 1 (including ginseng powder), peak 21 (protopanaxdiol) was detected and the rest was not detected (Fig. 2A). In the composition of Comparative Example 2 (including goat ginseng powder), peaks No. 15 (Rd2), No. 16 (F2), and No. 21 (protopanaxdiol) were detected (FIG. 2B), and the composition of Examples (including active ginseng + sprout ginseng powder) In, peaks 2 (Re), 15 (Rd2), 16 (F2), and 21 (protopanaxdiol) were all detected (FIG. 2C).
표 3에 나타낸 바와 같이, 진세노사이드 함량은 실시예의 음료용 프리믹스 조성물에서는 Re가 0.21 mg/g, Rd2는 0.09 mg/g, F2가 0.20 mg/g, 프로토파마사디올은 0.19 mg/g으로 측정되어, 비교예 1 및 비교예 2에 비하여 현저히 강화됨을 확인할 수 있다. As shown in Table 3, the ginsenoside content is 0.21 mg / g in Re in the premix composition for beverages of the Examples, 0.09 mg / g in Rd2, 0.20 mg / g in F2, and 0.19 mg / g in Protopamasadiol. It was measured, it can be confirmed that it is significantly enhanced compared to Comparative Example 1 and Comparative Example 2.
시험예Test example 3: 3: 페놀릭스Phenolic 및 And 플라보노이드스Flavonoids 함량 분석 Content analysis
제조예 2에서 제조된 실시예의 음료용 프리믹스 조성물과 비교예 1 및 2의 조성물의 페놀릭스와 플라보노이드 함량은 각각 Folin-Ciocalteu 페놀시약과 디에틸렌 글리콜 시약을 사용하여 비색법으로 수행하였다.The phenolics and flavonoid contents of the premix composition for beverages of Examples prepared in Preparation Example 2 and the compositions of Comparative Examples 1 and 2 were performed by colorimetry using Folin-Ciocalteu phenol reagent and diethylene glycol reagent, respectively.
<페놀릭스 함량><Phenolix content>
페놀릭스 함량은 각 조성물의 추출-농축액을 물로 100배 희석하고 이 희석용액 0.5 ml를 시험관에 정확하게 칭량하고 여기에 25% 탄산나트륨 용액을 동량 첨가하고 3분간 정치 후 다시 여기에 2 N Folin-Ciocalteu 발색 시약 0.25 ml를 첨가하여 37℃에서 1시간 가량 발색반응을 수행하였다. 반응 종료 후 적당히 원심분리 후 상등액을 750 nm에서 측정하여 흡광도 값을 탄닌산으로부터 작성된 표준검량곡선에 대입하여 mg/g으로 그 값을 산출하여 도 3a에 나타냈다.The phenolics content is diluted 100 times with extract-concentrate of each composition with water, 0.5 ml of this diluted solution is accurately weighed in a test tube, and the same amount of 25% sodium carbonate solution is added thereto, left for 3 minutes, and again, 2 N Folin-Ciocalteu develops 0.25 ml of the reagent was added to perform a color development reaction at 37 ° C. for about 1 hour. After the completion of the reaction, the supernatant was appropriately centrifuged and measured at 750 nm. The absorbance value was substituted into a standard calibration curve prepared from tannic acid, and the value was calculated in mg / g.
도 3a에 도시된 바와 같이, 페놀릭스 함량은 인삼 분말을 포함하는 비교예 1의 조성물에서는 0.02 mg/g으로 아주 극히 적은 양을 나타내었으나, 실시예의 음료용 프리믹스 조성물은 0.06 mg/g으로 현저히 증진된 함량을 나타냈다(도 3a).As shown in Figure 3a, the phenolics content of the composition of Comparative Example 1 containing ginseng powder showed a very small amount of 0.02 mg / g, but the premix composition for beverages of the Example significantly improved to 0.06 mg / g The content was shown (Fig. 3a).
<플라보노이드스 함량><Flavonoids content>
플라보노이드스 함량은 각 조성물의 추출-농축액을 물로 100배 희석하고 이 희석용액 0.5 ml를 에펜도르프 튜브에 넣은 후 1 N NaOH 용액 0.1 ml를 첨가하여 37℃에서 5분간 예비반응을 수행하였다. 이후 본 반응에서는 예비 반응물에 디에틸렌 글리콜 용액 1.0 ml를 첨가하여 37℃에서 1시간 발색 반응을 수행하고 420 nm에서 흡광도 값을 측정하고 루틴으로부터 작성된 표준검량곡선에 대입하여 그 함량을 mg/g으로 산출하여 도 3b에 나타냈다.The flavonoids content was diluted 100 times with the extract-concentrate of each composition with water, 0.5 ml of this dilution solution was placed in an Eppendorf tube, and 0.1 ml of 1 N NaOH solution was added to perform a preliminary reaction at 37 ° C for 5 minutes. Subsequently, in this reaction, 1.0 ml of diethylene glycol solution is added to the pre-reactant to perform a color development reaction at 37 ° C. for 1 hour, absorbance values are measured at 420 nm, and the content is expressed in mg / g by substituting it into a standard calibration curve prepared from Rutin. It was calculated and shown in Fig. 3B.
도 3b에 도시된 바와 같이, 플라보노이드스 함량 역시 비교예 1(0.03 mg/g) 및 비교예 2(0.05 mg/g)에 비하여 실시예의 조성물은 0.09 mg/g로 현저히 증진됨을 확인할 수 있다.As shown in Figure 3b, it can be seen that the flavonoids content was also significantly improved to 0.09 mg / g, compared to Comparative Example 1 (0.03 mg / g) and Comparative Example 2 (0.05 mg / g).
시험예Test example 4: 항산화 활성 분석 4: Antioxidant activity assay
제조예 2에서 제조된 실시예의 음료용 프리믹스 조성물과 비교예 1 및 2의 조성물의 항산화 활성 분석은 DPPH, ABTS 및 히드록실 라디칼 소거활성과 FRAP 환원력 측정 방법을 통해 수행하였다.Analysis of antioxidant activity of the premix composition for beverages of Examples prepared in Preparation Example 2 and those of Comparative Examples 1 and 2 was performed through DPPH, ABTS and hydroxyl radical scavenging activity and FRAP reducing power measurement methods.
<DPPH 라디칼 소거활성><DPPH radical scavenging activity>
DPPH 라디칼 소거활성은 각 조성물의 추출-농축액을 증류수로 100배 희석하여 분석시룔로 사용하였다. 분석시료 0.2 ml와 DPPH 용액 0.8 ml를 혼합하고 암실에서 30분간 반응시키고 그 반응물을 517 nm에서 흡광도를 측정하였다. DPPH 라디칼 소거활성은 음성 대조구의 경우 각 조성물 대신 증류수로 대체하여 상기 방법과 동일하게 수행하여 흡광도 차이를 아래와 같은 식에 대입하여 백분율(%)로 산출하였으며, 그 결과를 도 4a에 나타내었다:DPPH radical scavenging activity was used for analysis by diluting the extract-concentrate of each composition with distilled
라디칼 소거활성(%) =Radical scavenging activity (%) =
[1-(음성대조구 흡광도 ÷ 실험구 흡광도)] × 100[1- (absorbance of negative control ÷ absorbance of experimental sphere)] × 100
도 4a에 나타낸 바와 같이, 비교예 1(34.35%) 및 비교예 2(58.82%)에 비하여 실시예(67.67%)는 DPPH 라디칼 소거활성이 증진됨을 알 수 있다.As shown in FIG. 4A, it can be seen that the Example (67.67%) has enhanced DPPH radical scavenging activity compared to Comparative Example 1 (34.35%) and Comparative Example 2 (58.82%).
<ABTS 라디칼 소거활성><ABTS radical scavenging activity>
ABTS 라디칼 소거활성은 청색의 라디칼이 점차 무색으로 변색하는 즉, 항산화 활성에 따라 점점 퇴색하는 원리를 이용하여 측정하는 방법이다. 이 분석은 탈색반응이 1분 내에 빠르게 종료되므로 짧은 시간에 측정이 가능한 장점이 있다. ABTS 라디칼 소거활성은 우선 K2S2O8 시약과 메탄올을 2:1로 섞어 16시간 암실에서 ABTS 양이온 라디칼을 형성시키고 이를 다시 메탄올로 희석하여 최종 농도가 732 nm에서 흡광도 값이 0.8±0.2가 되도록 조절한 ABTS 시약을 사용한다.ABTS radical scavenging activity is a method of measuring by using the principle that blue radicals gradually colorless, that is, gradually fade according to antioxidant activity. This analysis has the advantage of being able to measure in a short time since the bleaching reaction ends quickly within 1 minute. ABTS radical scavenging activity is first mixed with K 2 S 2 O 8 reagent and methanol 2: 1 to form ABTS cationic radicals in the dark for 16 hours and diluted with methanol again, resulting in an absorbance value of 0.8 ± 0.2 at a final concentration of 732 nm. Use ABTS reagent as adjusted as possible.
구체적으로는 ABTS 시약 0.9 ml에 각각의 분석시료 0.1 ml를 첨가하여 1분간 반응시키고 신속히 732 nm에서 흡광도를 측정하였다. 음성 대조구는 시료 대신 증류수를 사용하여 동일한 방법으로 수행하여 흡광도의 차이를 상기 식에 의해 백분율(%)로 산출하였으며, 그 결과를 도 4b에 나타내었다.Specifically, 0.1 ml of each analysis sample was added to 0.9 ml of ABTS reagent, reacted for 1 minute, and absorbance was rapidly measured at 732 nm. The negative control was performed in the same way using distilled water instead of the sample, and the difference in absorbance was calculated as a percentage (%) by the above formula, and the results are shown in FIG. 4B.
도 4b에 나타낸 바와 같이, 비교예 1과 비교예 2의 조성물은 각각 43%와 55%를 나타내었으나 본 발명에 따른 실시예의 조성물은 72%로 크게 증진됨을 확인할 수 있다.As shown in Fig. 4b, the compositions of Comparative Example 1 and Comparative Example 2 showed 43% and 55%, respectively, but it can be seen that the composition of the Example according to the present invention is greatly enhanced to 72%.
<히드록실 라디칼 소거활성><Hydroxyl radical scavenging activity>
히드록실 라디칼 소거활성은 10 mM FeSO4 7H20-EDTA 0.2 ml, 10 mM 2-데옥시리보스 0.2 ml, 10 mM H202 0.2 ml와 각각의 분석시료 1.4 ml를 혼합하여 37℃에서 4시간 발색반응을 수행하였다. 반응 후 이 반응물에 1% 트리클로바비투르산과 2.8% 트리클로아세트산을 각각 1.0 ml 첨가하여 100℃에서 20분간 가열하여 다시 발색시키고 이를 적당히 냉각시켜 520 nm에서 흡광도를 측정하였다. 히드록실 라디칼 소거활성은 상기 기술된 바와 동일하게 산출하여 도 4c에 나타냈다.The hydroxyl radical scavenging activity was 4 at 37 ° C. by mixing 0.2 ml of 10 mM FeSO 4 7H 2 0-EDTA, 0.2 ml of 10 mM 2-deoxyribose, 0.2 ml of 10
도 4c에 나타낸 바와 같이, 비교예 1과 2의 조성물은 각각 16%와 25%로 라티칼 소거활성이 저조하였으나 실시예는 54.76%로 라디칼 소거활성이 크게 증진됨을 확인할 수 있다.As shown in Fig. 4c, the compositions of Comparative Examples 1 and 2 had a low radical scavenging activity at 16% and 25%, respectively, but it was confirmed that the radical scavenging activity was greatly enhanced at 54.76% in Examples.
<< FRAPFRAP 환원력> Reducing power>
FRAP(ferric reducing antioxidant power) 환원력은 산화환원 반응 중 환원에 해당되는 것으로 Fe3 +이온을 Fe2 +이온으로 환원시킬 때 흡광도 수치를 측정하여 이를 항산화 활성의 지표로써 나타낸 것이다.FRAP (ferric reducing antioxidant power) reducing power by measuring the absorbance value when the reduction of the Fe + 3 ions to be available for the reduction of the redox reaction as Fe 2 + ion shows this as an indicator of antioxidant activity.
구체적으로는 30 mM 아세테이트 버퍼(30 mM, pH 3.6), TPTZ 시약(10 mM, 6 N 염산에 녹인)과 FeCl3 용액(20 mM, 증류수에 녹인)을 100:10:10(v/v/v)의 비율로 먼저 혼합하여 FRAP 시약을 조제하였다. FRAP 시약을 37℃의 수욕상에서 15분간 예비반응시켜 두고 각각의 분석시료를 시험관에 0.05 ml씩 첨가하고 여기에 미리 반응해두었던 FRAP 시약을 0.85 ml씩 첨가하여 상기와 같은 방법으로 37℃에서 15분 반응시켰다. 반응 후 일부분을 593 nm에서 흡광도를 측정하여 도 4d에 나타냈다.Specifically, 30 mM acetate buffer (30 mM, pH 3.6), TPTZ reagent (10 mM, dissolved in 6 N hydrochloric acid) and FeCl 3 solution (20 mM, dissolved in distilled water) 100: 10: 10 (v / v / FR) reagent was prepared by first mixing at a ratio of v). FRAP reagent was pre-reacted for 15 minutes in a water bath at 37 ° C., and 0.05 ml of each analytical sample was added to the test tube, and 0.85 ml of FRAP reagent, which had been previously reacted thereto, was added thereto. To react. After the reaction, a portion of the absorbance at 593 nm was measured and shown in FIG. 4D.
도 4d에 도시된 바와 같이, 비교예 1(0.915) 및 비교예 2(1.516)에 비하여 실시예(1.994)는 FRAP 환원력도 현저히 증진됨을 알 수 있다. As shown in Figure 4d, it can be seen that the comparative example 1 (0.915) and the comparative example 2 (1.516) in Example (1.994) FRAP reducing power is also significantly improved.
Claims (5)
상기 활성산양삼 분말은 산양삼을 100℃에서 30~60분간 증숙한 후 수탁번호 KACC91848P로 기탁된 락토바실러스 플란타륨 P1201 균주와 수탁번호 KACC 92159P로 기탁된 락토바실러스 브레비스 WCP02 균주의 복합 종균으로 발효하여 40∼55℃에서 3~5일 건조하고 100 메쉬 이하로 분쇄하여 제조된 것이고,
상기 새싹삼 분말은 새싹삼 전초를 40∼55℃에서 3~5일 건조하고 100 메쉬 이하로 분쇄하여 제조된 것이고,
진세노사이드 Re가 0.21 mg/g, Rd2가 0.09 mg/g, F2가 0.20 mg/g, 및 프로토파낙사디올이 0.19 mg/g으로 강화된 것을 특징으로 하는,
진세노사이드 Re, Rd2, F2 및 프로토파낙사디올이 강화된 음료용 프리믹스 조성물.
Contains 1 to 3% by weight of active goat ginseng powder, 2 to 8% by weight of sprouted ginseng powder, 1 to 3% by weight of taurine, and the remaining powdery sugars,
The active goat ginseng powder is fermented into a composite spawn of a Lactobacillus plantarum P1201 strain deposited with accession number KACC91848P and a Lactobacillus brevis WCP02 strain deposited with accession number KACC 92159P after steaming the wild ginseng for 30-60 minutes at 100 ° C. It is prepared by drying at ∼55 ℃ for 3 ~ 5 days and grinding to 100 mesh or less,
The sprout sprout powder was prepared by drying the sprout sprout outpost at 40-55 ° C. for 3 to 5 days and crushing to 100 mesh or less,
Characterized in that ginsenoside Re was enhanced to 0.21 mg / g, Rd2 to 0.09 mg / g, F2 to 0.20 mg / g, and protopanaxadiol to 0.19 mg / g,
Ginsenoside Re, Rd2, F2 and protopanaxadiol enhanced beverage premix composition.
ⅰ) 산양삼을 100℃에서 30~60분간 증숙한 후 수탁번호 KACC91848P로 기탁된 락토바실러스 플란타륨 P1201 균주와 수탁번호 KACC 92159P로 기탁된 락토바실러스 브레비스 WCP02 균주의 복합 종균으로 발효하여 40∼55℃에서 3~5일 건조하고 100 메쉬 이하로 분쇄하여 활성산양삼 분말을 제조하는 단계;
ⅱ) 새싹삼 전초를 40∼55℃에서 3~5일 건조하고 100 메쉬 이하로 분쇄하여 새싹삼 분말을 제조하는 단계; 및
ⅲ) 활성산양삼 분말 1~3 중량%, 새싹삼 분말 2~8 중량%, 타우린 1~3 중량% 및 나머지 분말상 당류를 혼합하는 단계를 포함하고,
상기 조성물은 진세노사이드 Re가 0.21 mg/g, Rd2가 0.09 mg/g, F2가 0.20 mg/g, 및 프로토파낙사디올이 0.19 mg/g으로 강화된 것을 특징으로 하는,
진세노사이드 Re, Rd2, F2 및 프로토파낙사디올가 강화된 음료용 프리믹스 조성물의 제조방법.Ginsenoside Re, Rd2, F2 and protopanaxadiol according to claim 1, the method for preparing a premix composition for beverages, wherein the method is
Iv) After fermenting wild ginseng at 100 ℃ for 30 ~ 60 minutes, fermentation is performed with a complex strain of Lactobacillus plantarum P1201 strain deposited with accession number KACC91848P and Lactobacillus brevis WCP02 strain deposited with accession number KACC 92159P at 40∼55 ℃ Drying in 3-5 days and pulverized to 100 mesh or less to prepare active ginseng powder;
Ii) preparing sprout sprout powder by drying the sprout sprout outpost at 40-55 ° C. for 3 to 5 days and crushing to 100 mesh or less; And
Iv) mixing 1 to 3% by weight of active wild ginseng powder, 2 to 8% by weight of sprouted ginseng powder, 1 to 3% by weight of taurine and the remaining powdered sugars,
The composition is characterized in that ginsenoside Re is enhanced to 0.21 mg / g, Rd2 to 0.09 mg / g, F2 to 0.20 mg / g, and protopanaxadiol to 0.19 mg / g,
Ginsenoside Re, Rd2, F2 and protopanaxadiol is a method for preparing a premix composition for enhanced beverage.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180146396A KR102090408B1 (en) | 2018-11-23 | 2018-11-23 | Premixed composition for beverage containing increased ginsenoside Re, Rd2, F2 and protopanaxdiol and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180146396A KR102090408B1 (en) | 2018-11-23 | 2018-11-23 | Premixed composition for beverage containing increased ginsenoside Re, Rd2, F2 and protopanaxdiol and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102090408B1 true KR102090408B1 (en) | 2020-04-07 |
Family
ID=70290932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180146396A KR102090408B1 (en) | 2018-11-23 | 2018-11-23 | Premixed composition for beverage containing increased ginsenoside Re, Rd2, F2 and protopanaxdiol and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102090408B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220051584A (en) * | 2020-10-19 | 2022-04-26 | 경상국립대학교산학협력단 | Fermentation composition of mountain-cultivated ginseng having increased ginsenoside Rd, Rc and Protopanaxadiol by using Tricholoma matsutake mycelium and preparation method thereof |
KR20220058995A (en) * | 2020-11-02 | 2022-05-10 | 경상국립대학교산학협력단 | Fermentation composition of sprouts of mountain-cultivated ginseng having increased ginsenoside Rg3 and Protopanaxadiol, Rutin, Chlorogenic acid and Essential amid acids by using Tricholoma matsutake mycelium and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100866504B1 (en) * | 2008-09-23 | 2008-11-11 | 주식회사 비티씨 | Microorganisms for fermentation of red ginseng and food composition containing fermented red ginseng |
KR20110111142A (en) * | 2010-04-02 | 2011-10-10 | (주)바이오토피아 | Processing method of ginseng for enhancing contents of active components in the ginseng |
KR20110130746A (en) * | 2010-05-28 | 2011-12-06 | (주)카페베네 | Composition for premix of red ginseng products eliminated bittering taste and preparation method thereof |
KR20170085990A (en) * | 2016-01-15 | 2017-07-25 | 김유근 | Method of increase the bioactive effectiveness of sprout ginseng |
-
2018
- 2018-11-23 KR KR1020180146396A patent/KR102090408B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100866504B1 (en) * | 2008-09-23 | 2008-11-11 | 주식회사 비티씨 | Microorganisms for fermentation of red ginseng and food composition containing fermented red ginseng |
KR20110111142A (en) * | 2010-04-02 | 2011-10-10 | (주)바이오토피아 | Processing method of ginseng for enhancing contents of active components in the ginseng |
KR20110130746A (en) * | 2010-05-28 | 2011-12-06 | (주)카페베네 | Composition for premix of red ginseng products eliminated bittering taste and preparation method thereof |
KR20170085990A (en) * | 2016-01-15 | 2017-07-25 | 김유근 | Method of increase the bioactive effectiveness of sprout ginseng |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220051584A (en) * | 2020-10-19 | 2022-04-26 | 경상국립대학교산학협력단 | Fermentation composition of mountain-cultivated ginseng having increased ginsenoside Rd, Rc and Protopanaxadiol by using Tricholoma matsutake mycelium and preparation method thereof |
KR102545365B1 (en) * | 2020-10-19 | 2023-06-20 | 경상국립대학교산학협력단 | Fermentation composition of mountain-cultivated ginseng having increased ginsenoside Rd, Rc and Protopanaxadiol by using Tricholoma matsutake mycelium and preparation method thereof |
KR20220058995A (en) * | 2020-11-02 | 2022-05-10 | 경상국립대학교산학협력단 | Fermentation composition of sprouts of mountain-cultivated ginseng having increased ginsenoside Rg3 and Protopanaxadiol, Rutin, Chlorogenic acid and Essential amid acids by using Tricholoma matsutake mycelium and preparation method thereof |
KR102557683B1 (en) * | 2020-11-02 | 2023-07-20 | 경상국립대학교산학협력단 | Fermentation composition of sprouts of mountain-cultivated ginseng having increased ginsenoside Rg3 and Protopanaxadiol, Rutin, Chlorogenic acid and Essential amid acids by using Tricholoma matsutake mycelium and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102048167B (en) | Additive of radiation-resistant functional beverage, and additive-containing barley green milk wine and tea beverage | |
KR101467837B1 (en) | Manufacturing method of fermented red ginseng extract with enhanced ginsenosides Rg3 and antioxidant activity | |
KR102386296B1 (en) | Complex-fermented composition of Fabaton soybean leaves and Schisandra chinensis having enhanced anti-diabetic and anti-obesity effects and preparation method thereof | |
KR102090408B1 (en) | Premixed composition for beverage containing increased ginsenoside Re, Rd2, F2 and protopanaxdiol and preparation method thereof | |
Ariff et al. | Recent trends in Kombucha: Conventional and alternative fermentation in development of novel beverage | |
JP4010907B2 (en) | Method for producing fermented plant and lactic acid fermented product | |
KR101372400B1 (en) | A manufacturing method of red ginseng staf4h with enhanced trace ginsenoside | |
KR101341552B1 (en) | Manufacturing method of codonopsis lanceolata vinegar with increased antioxidant activity | |
KR101917822B1 (en) | Production method of cirsimaritin fortified thistle concentrate using Lactobacillus plantarum KCCM 11322 strain | |
KR102133721B1 (en) | functional food composition for antioxidant effect comprising fermented permission leaf | |
KR20160126591A (en) | Method of producing ginseng fermented extract, Ginseng fermented extract produced by the same and Health functional foods comprising the same | |
KR20190138066A (en) | kombucha manufacturing method | |
KR102094084B1 (en) | Aged and complex-fermented mountain-cultivated ginseng having increased ginsenosides of human body absorption type and omega-6 fatty acid, and preparation method thereof | |
KR20190042329A (en) | Manufacturing method of curcuma root brown rice vinegar using two stages fermentation | |
KR102168192B1 (en) | Healthful mixed tea development using fermented herbs, fruits and shiitake | |
KR102151573B1 (en) | Herb vinegar and manufacturing method thereof | |
KR102464052B1 (en) | Composition of complex-fermented sprout ginseng having increased ginsenoside F2, Rg3, Rd2 and compound K, chlorogenic acid, coumaric acid, catechin and quercetin, and preparation method thereof | |
KR20190079836A (en) | Method for producing fermented barley sprout with enhanced saponarin, isovitexin and luteolin using novel Lactobacillus fermentum strain | |
KR102132537B1 (en) | Platycodon grandiflorum Liquid composition for stick-type container having increased ginsenosides of human body absorption type, and preparation method thereof | |
KR20190072923A (en) | Antioxidant and Immune-enhancing functional beverage and food composition comprising the extract of edible flowers fermented by lactic acid bacteria and preparation method of the same | |
KR102487459B1 (en) | Manufacturing method of health food having antioxidant activity containing fermented polygonum multiflorum complex extracts and the health food having antioxidant activity thereby | |
CN107927492A (en) | A kind of probiotics composite beverage and preparation method thereof | |
KR20220076950A (en) | Process for preparing fermented kombucha with microbiome | |
KR20220093287A (en) | Process for preparing fermented drink with microbiome | |
KR102030902B1 (en) | Fermentation method of lactic acid bacteria using fruit of Prunus sp. and its use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GRNT | Written decision to grant |